Results 31 to 40 of about 11,492 (193)

Correlation between the Severity of Metabolic Dysfunction-Associated Fatty Liver Disease and Serum Uric Acid to Serum Creatinine Ratio

International Journal of Endocrinology, 2023
Purpose. As one of the most common chronic liver diseases, metabolic dysfunction-associated fatty liver disease (MAFLD) had different prognoses between mild and moderate-severe levels.
Jing Liu, Hongye Peng, Che Wang, Yutong Wang, Rongrui Wang, Jixiang Liu, Tianhui Zhou, Shukun Yao   +7 more
doaj   +1 more source

Two years on, a perspective on MAFLD

, 2023
To provide clarity for research studies and clinical care, a set of positive criteria for adults and children with metabolic (dysfunction) associated fatty liver disease (MAFLD) was recently published and has subsequently been widely endorsed.
Mohammed Eslam, Jacob George
core   +1 more source

A Scientometric Assessment of MAFLD in Children and Adolescents from 2007–2024

National Board of Examinations Journal of Medical Sciences
Purpose: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a growing concern in children and adolescents, with prevalence estimated between 7.6% and 9.6%.
Raju Vaishya, Anupam Sibal, Brij Mohan Gupta, Ghouse Modin N Mamdapur, Abhishek Vaish   +4 more
doaj   +1 more source

Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity

Diabetes, Metabolic Syndrome and Obesity, 2021
Mona A Hegazy,1 Ibrahim Abd ALgwad,1 Soheir Abuel Fadl,1 Mohamed Sayed Hassan,1 Laila Ahmed Rashed,2 Maha A Hussein1 1Internal Medicine Department, Kasr Al-Aini Hospitals, Cairo University, Cairo, Egypt; 2Biochemistry Department, Kasr Al-Aini Hospitals ...
Hegazy MA, Abd ALgwad I, Abuel Fadl S, Sayed Hassan M, Ahmed Rashed L, Hussein MA   +5 more
doaj  

Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff

Diabetes, Metabolic Syndrome and Obesity, 2023
Daya Zhang,1,* Lijun Zhang,2,* Shiju Chen,1,* Runxiang Chen,1 Xiaodong Zhang,1 Feihu Bai3,4 1Graduate School, Hainan Medical University, Haikou, People’s Republic of China; 2Medical Examination Center, The Second Affiliated Hospital of Hainan
Zhang D, Zhang L, Chen S, Chen R, Zhang X, Bai F   +5 more
doaj  

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis [PDF]

Clinical and Molecular Hepatology
Background/Aims The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear.
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George   +13 more
doaj   +1 more source

Bioengineered Exosome‐Loaded Immunomodulatory Bioadhesive Spray Reverses Liver Fibrosis and Metabolic Dysfunction That Triggers Beneficial Gut‐Liver Crosstalk in Chronic Fatty Liver Disease

Advanced Science, EarlyView.
Umbilical cord stem cell‐derived exosomes encapsulated in an immunomodulatory bioadhesive hydrogel spray enable localized therapy, sustained vesicle delivery, macrophage polarization, suppress systemic inflammation, and mitigate glucose and insulin homeostasis impairments in MAFLD.
Triya Saha, Ayushi Mairal, Shreya Mehrotra, Shiv K. Sarin, Ashok Kumar   +4 more
wiley   +1 more source

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

, 2023
Metabolic dysfunction associated fatty liver disease (MAFLD) has been recently recognized as a new global chronic liver disease entity with non-alcoholic fatty liver disease (NAFLD) associated with overweight/obesity or type 2 diabetes mellitus (T2DM ...
Mukund P. Srinivasan, Kamlesh K. Bhopale
core   +1 more source

Risk of the Development of Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Rheumatoid Arthritis

İstanbul Medical Journal, 2023
Introduction: Individuals diagnosed with rheumatoid arthritis (RA) face a heightened risk of developing metabolic dysfunction-associated fatty liver disease (MAFLD).
Murat Aydın, Berrin Aksakal, Sema Basat
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source